View Author
dai: 163934053
scopus: 6601983607
Sleijfer, S.
(Stefan Sleijfer)Supervisor (promotor) of 1 dissertation
patient cancer tumor study treatment breast expression therapy level blood factor response sarcoma tissue mirna metastatic disease survival sample sunitinib phase group imatinib trial breast cancer receptor number activity result tumor cells chemotherapy oncol analysis effect ifosfamide marker combination table plasma prognostic month t cells oncology research detection assay transduction protein bevacizumab concentration carcinoma breast cancer patients doxorubicin inhibitor method agent toxicity kinase stromal 0.00 growth tumour target stromal tumors tissue sarcomas mutation control tamoxifen lymphocytes t-cell serum model change randomized cell carcinoma grade signi association outcome cancer patients
10 Most Recent Publications
|
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue
(Article)
Mostert, B. Jiang, Y. Spoel, P. van der RamÃrez-Moreno, R. Verhoef, C. IJzermans, J.N.M. Gratama, J-W. Foekens, J.A. Sleijfer, S. Martens, J.W.M. Sieuwerts, A.M. Wang, H. Bolt-de Vries, J. Biermann, K. Kraan, J. Lalmahomed, Z.S. Galen, A. van Weerd, V. de |
2013-07-01
|
|
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
(Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Steenbergen, S.L.C. van Luider, B.A. Groot, C. Krimpen, B.A. van Vulto, A.G. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W. |
2013-05-01
|
|
Tijd om persoonlijk te worden
(Inaugural Lecture)
Sleijfer, S. |
2012-04-20
|
|
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: Clinical and prognostic implications
(Article)
Gaal, J.C. van Flucke, U.E. Roeffen, M.H.S. Bont, E.S.J.M. de Sleijfer, S. Mavinkurve-Groothuis, A.M.C. Suurmeijer, A.J.H. Graaf, W.T.A. van der Versleijen-Jonkers, Y.M.H. |
2012-01-20
|
|
Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
(Article)
Meiracker, A.H. van den Danser, A.H.J. Sleijfer, S. Kappers, M.H.W. |
2011-10-19
|
|
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression
(Article)
Kappers, M.H.W. Esch, J.H.M. van Visser, T.J. Smedts, F. Krijger, R.R. de Eechoute, K. Mathijssen, R.H.J. Sleijfer, S. Leijten, F.P.J. Danser, A.H.J. Meiracker, A.H. van den |
2011-10-01
|
|
Circulating tumor cell isolation and diagnostics: Toward routine clinical use
(Article)
Stolpe, A. van de Pantel, K. Sleijfer, S. Terstappen, L.W.M.M. Den Toonder, J.M.J. |
2011-09-15
|
|
The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system
(Article)
Kappers, M.H.W. Smedts, F. Horn, T. Esch, J.H.M. van Sleijfer, S. Leijten, F.P.J. Wesseling, S. Strevens, H. Danser, A.H.J. Meiracker, A.H. van den |
2011-08-01
|
|
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
(Article)
Schaik, R.H.N. van Kok, M. Span, P.N. Laarhoven, H.W.M. van Sleijfer, S. Foekens, J.A. Linn, S.C. Berns, E.M.J. Sweep, F.C.J. Vliet, M. van Fessem, M.A. van Meijer van Gelder, M.E. Seynaeve, C.M. Lindemans, J. Wesseling, J. Veer, L.J. van 't |
2011-08-01
|
|
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes
(Article)
Riaz, M. Berns, P.M.J.J. Foekens, J.A. Martens, J.W.M. Sieuwerts, A.M. Ruigrok-Ritstier, K. Weerd, V. de Groenewoud, A. Uitterlinden, A.G. Look, M.P. Klijn, J.G.M. Sleijfer, S. |
2011-07-12
|
